Compare · ADGI vs NVO
ADGI vs NVO
Side-by-side comparison of Adagio Therapeutics Inc. (ADGI) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADGI and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 242.8x ADGI ($754.3M).
- NVO has hit the wire 8 times in the past 4 weeks while ADGI has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 11 for ADGI).
- Company
- Adagio Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $4.63+0.87%
- $41.01-4.51%
- Market cap
- $754.3M
- $183.15B
- 1M return
- -
- -10.44%
- 1Y return
- -
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 8
- Recent ratings
- 11
- 25
Adagio Therapeutics Inc.
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Its lead product candidate is the ADG20, a neutralizing antibody that is in Phase II/III clinical trials for the treatment and prevention of coronavirus disease. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. Adagio Therapeutics, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ADGI
- Invivyd to Participate at Cowen's 43rd Annual Healthcare Conference
- Invivyd Announces Changes to Executive Team
- Adagio Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop
- SEC Form 4 filed by Dabora Rebecca
- SEC Form 4 filed by Andersen Jill
- SEC Form 4 filed by Schmidt Peter
- SEC Form 4 filed by Gowler Jeremy
- SEC Form 3 filed by new insider Gowler Jeremy
- SEC Form 4 filed by Hering David
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care